Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females
Autore:
Walsh, KM; Leen, E; Lean, MEJ;
Indirizzi:
Univ Glasgow, Royal Infirm, Dept Human Nutr, Glasgow G31 2ER, Lanark, Scotland Univ Glasgow Glasgow Lanark Scotland G31 2ER ow G31 2ER, Lanark, Scotland Univ Glasgow, Royal Infirm, Dept Radiol, Glasgow G31 2ER, Lanark, ScotlandUniv Glasgow Glasgow Lanark Scotland G31 2ER ow G31 2ER, Lanark, Scotland
Titolo Testata:
INTERNATIONAL JOURNAL OF OBESITY
fascicolo: 10, volume: 23, anno: 1999,
pagine: 1009 - 1015
SICI:
0307-0565(199910)23:10<1009:TEOSOR>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSTPRANDIAL THERMOGENESIS; CARDIAC-OUTPUT; METABOLIC-RATE; DEXFENFLURAMINE; FENFLURAMINE; RESPONSES; EXERCISE; HUMANS; WEIGHT;
Keywords:
sibutramine; weight loss; thermogenesis; energy expenditure; obesity; cardiac output;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Lean, MEJ Univ Glasgow, Royal Infirm, Dept Human Nutr, Queen Elizabeth Bldg, GlasgowG31 2ER, Lanark, Scotland Univ Glasgow Queen Elizabeth Bldg Glasgow Lanark Scotland G31 2ER
Citazione:
K.M. Walsh et al., "The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females", INT J OBES, 23(10), 1999, pp. 1009-1015

Abstract

BACKGROUND: Sibutramine, an inhibitor of serotonin and noradrenaline uptake, reduces appetite to cause weight loss. This study tested the hypothesis that an increase in energy expenditure also contributes to this weight loss. In addition, the effects of sibutramine on adrenaline induced changes in heart rate and cardiac output were determinedMETHODS: Nineteen obese females randomly received either sibutramine 15 mgdaily or placebo for 12 weeks along with dietary advice. Resting energy expenditure (REE) was measured and then energy expenditure was measured during a 30 min infusion of adrenaline (25 ng/min/kg IBW). Cardiac output and heart rate, measured by Duplex Colour Doppler ultrasonography, were similarlymeasured in the basal state and post adrenaline. All measurements were recorded at baseline and then after 12 weeks. RESULTS: Ten patients who received sibutramine reduced their weight by 8.1+/- 3.8% while 9 placebo treated subjects reduced their weight by 5.1 +/- 4.4%, P = 0.13. In absolute terms, REE decreased in placebo subjects from 1500 +/- 201 kcal/24 h to 1357 +/- 231 kcal/24 h (9.4 +/- 9.9%) and in sibutramine subjects from 1540 +/- 184 kcal/24 h to 1444 +/- 128 kcal/24 h (5.3 /- 12.0%), P = 0.77. The increased weight loss in the sibutramine group was associated with an increase in the FFM adjusted REE (2.2 +/- 16.1%) unlike the expected decrease (5.8 +/- 9.5%) in the placebo group (P = 0.11). There was some suggestion (P = 0.09) that the usual positive correlation between loss of weight and decline in REE was lost in the sibutramine group (r =-0.30) compared with placebo (r = 0.35). There was a negative correlation between loss of FFM and decline in REE/kg FFM and (P = 0.029) which was notevident in placebo (P = 0.83). Adrenaline induced energy expenditure was similar in the two groups at the end of the 12 week period and there were nosignificant cardiovascular changes between the two groups. CONCLUSIONS: Sibutramine limits the decline in REE associated with weight loss, equivalent to about 100 kcal/d. This could allow greater numbers of people to maintain a greater degree of weight loss.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 10:20:09